Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 4:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 52 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Rejection Chronic Renal Clear all
Enrolling by invitation Phase 2 Interventional

Belumosudil for Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation

NCT06751602
View directory record Official record
Conditions
Rejection Chronic Renal
Interventions
Belumosudil 200 mg QD, Placebo
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 29, 2026, 4:53 AM EDT
Recruiting Phase 2Phase 3 Interventional

Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile

NCT03321656
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Tacrolimus, Envarsus XR
Drug
Lead sponsor
Roberto Gedaly
Other
Eligibility
18 Years to 75 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 29, 2026, 4:53 AM EDT
Completed No phase listed Observational

Proteogenomic Biomarker Panels in a Serial Blood & Urine Monitoring Study of Kidney Transplant Recipients

NCT01289717
View directory record Official record
Conditions
Kidney Transplant, Kidney Transplantation
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
5
States / cities
Phoenix, Arizona • La Jolla, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 29, 2026, 4:53 AM EDT
Completed Phase 3 Interventional Results available

Extended Release Tacrolimus vs. Twice-Daily Tacrolimus

NCT03289650
View directory record Official record
Conditions
End Stage Renal Disease, Rejection of Renal Transplant
Interventions
Tacrolimus, Tacrolimus Extended Release Oral Tablet [Envarsus]
Drug
Lead sponsor
Lorenzo Gallon
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 29, 2026, 4:53 AM EDT
Active, not recruiting Phase 1 Interventional

Immunological Tolerance in Patients With Mismatched Kidney Transplants

NCT05806749
View directory record Official record
Conditions
End Stage Kidney Disease, Immunological Tolerance, Kidney Transplant Failure and Rejection, Chronic Kidney Diseases
Interventions
Donor CD34+, CD3+. and belumosudil
Combination Product
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 29, 2026, 4:53 AM EDT
Completed Phase 3 Interventional Results available

Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate Sodium

NCT01680861
View directory record Official record
Conditions
Transplant; Failure, Kidney
Interventions
Tacrolimus, Everolimus, Enteric Coated Mycophenolate Sodium (EC-MPS), Corticosteroids
Drug
Lead sponsor
Gaetano Ciancio
Other
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 29, 2026, 4:53 AM EDT
Enrolling by invitation Phase 2 Interventional

Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients

NCT06126380
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
AT-1501, Tacrolimus
Drug
Lead sponsor
Eledon Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
26
States / cities
Los Angeles, California • Orange, California • Sacramento, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 29, 2026, 4:53 AM EDT
Recruiting Phase 1Phase 2 Interventional

Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant

NCT05027906
View directory record Official record
Conditions
Prevention of Rejection in Kidney Transplant
Interventions
AT-1501
Drug
Lead sponsor
Eledon Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 29, 2025 · Synced Oct 29, 2026, 4:53 AM EDT
Completed Phase 4 Interventional

Reference Group Trial for The ONE Study

NCT01656135
View directory record Official record
Conditions
End-stage Renal Failure, Kidney Graft Rejection
Interventions
Blood drawing for immune monitoring and questionnaires
Other
Lead sponsor
University of Regensburg
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
San Francisco, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2016 · Synced Oct 29, 2026, 4:53 AM EDT
Completed No phase listed Observational

Longitudinal Changes in Donor-Derived Cell-Free DNA With Tocilizumab Treatment for Chronic Antibody-Mediated Rejection

NCT03859388
View directory record Official record
Conditions
Rejection Chronic Renal, Kidney Transplant Rejection
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 29, 2026, 4:53 AM EDT
Terminated Phase 3 Interventional Results available

Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients

NCT03744910
View directory record Official record
Conditions
Antibody-mediated Rejection
Interventions
Clazakizumab, Physiologic saline solution
Biological · Drug
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years to 75 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
49
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Oct 29, 2026, 4:53 AM EDT
Enrolling by invitation Phase 2 Interventional

Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation

NCT05285878
View directory record Official record
Conditions
Interstitial Fibrosis, Kidney Transplant; Complications, Kidney Transplant Rejection, Kidney Transplant Failure and Rejection, Kidney Transplant Failure, Kidney Failure, Chronic, Graft Rejection
Interventions
Fingolimod, Placebo
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 29, 2026, 4:53 AM EDT
Completed No phase listed Observational

VIRTUUS Children's Study

NCT03719339
View directory record Official record
Conditions
Renal Transplant Rejection, Pediatric Kidney Disease, End Stage Renal Disease, Nephropathy, BK Virus (Nephropathy), Antibody-mediated Rejection, Acute Cellular Graft Rejection
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Years to 18 Years
Enrollment
445 participants
Timeline
2017 – 2026
U.S. locations
12
States / cities
La Jolla, California • Los Angeles, California • Palo Alto, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 29, 2026, 4:53 AM EDT
Completed No phase listed Observational

A Retrospective Multicenter Study to Determine 5-Year Clinical Outcomes in Subjects Previously Enrolled in the CTOT-01 Study

NCT01974999
View directory record Official record
Conditions
Kidney Disease, Kidney Failure, End Stage Renal Disease
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
5
States / cities
New Haven, Connecticut • Atlanta, Georgia • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 29, 2026, 4:53 AM EDT
Not listed Phase 4 Interventional

Belatacept With Early Steroid Withdrawal rATG and Everolimus in Renal Transplantation (BETTER Trial)

NCT04849533
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
Belatacept, Everolimus, mycophenolate mofetil, corticosteroids, rabbit antithymocyte globulin
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Oct 29, 2026, 4:53 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant

NCT03380962
View directory record Official record
Conditions
Kidney Failure, Chronic, End-Stage Renal Disease, Transplant Glomerulopathy, Transplant;Failure,Kidney, Kidney Transplant Failure and Rejection, Antibody-mediated Rejection, Kidney Transplant; Complications
Interventions
Clazakizumab
Drug
Lead sponsor
Stanley Jordan, MD
Other
Eligibility
15 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 29, 2026, 4:53 AM EDT
Terminated No phase listed Observational

Personalization of Immunosuppressive Treatment for Organ Transplant Recipients

NCT05747053
View directory record Official record
Conditions
Kidney Injury, Kidney Failure, Kidney Failure, Chronic, Kidney Failure, Acute, Kidney Diseases, Kidney Transplant Rejection, Kidney Transplant Infection, Kidney Transplant; Complications, Kidney Disease, Chronic, Kidney Ischemia
Interventions
AlloSure, PAXGene
Diagnostic Test
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 80 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 26, 2024 · Synced Oct 29, 2026, 4:53 AM EDT
Completed No phase listed Observational

Genomics of Chronic Renal Allograft Rejection (The GoCAR Study)

NCT00611702
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Kidney biopsy
Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
4
States / cities
Chicago, Illinois • Ann Arbor, Michigan • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 14, 2015 · Synced Oct 29, 2026, 4:53 AM EDT
Withdrawn Phase 4 Interventional

Belatacept in Kidney Transplantation of Moderately Sensitized Patients

NCT02130817
View directory record Official record
Conditions
End Stage Renal Disease, Antibody Mediated Rejection
Interventions
Belatacept, Tacrolimus withdrawal, Plasmapheresis/Intravenous Immunoglobulin G, Thymoglobulin (ATG), Myfortic, Steroids
Drug · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 17, 2018 · Synced Oct 29, 2026, 4:53 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation

NCT05983770
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
AT-1501, Tacrolimus
Drug
Lead sponsor
Eledon Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
27
States / cities
Los Angeles, California • Orange, California • Sacramento, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 29, 2026, 4:53 AM EDT
Terminated Phase 4 Interventional Results available

Tacrolimus to Sirolimus Conversion for Delayed Graft Function

NCT00931255
View directory record Official record
Conditions
Kidney Transplant, Delayed Graft Function
Interventions
Tacrolimus, Sirolimus
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 29, 2026, 4:53 AM EDT
Recruiting No phase listed Observational

Proteogenomic Monitoring and Assessment of Kidney Transplant Recipients

NCT01531257
View directory record Official record
Conditions
Acute Rejection (AR) of Transplanted Kidney, Chronic Allograft Nephropathy (CAN), Interstitial Fibrosis (IF), Tubular Atrophy (TA)
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 29, 2026, 4:53 AM EDT
Completed Phase 3 Interventional Results available

Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients

NCT00975000
View directory record Official record
Conditions
Chronic Allograft Nephropathy, Chronic Kidney Disease, Chronic Renal Failure, Disordered Mineral Metabolism, End Stage Renal Disease, Hyperparathyroidism, Hypophosphatemia, Kidney Disease, Kidney Transplantation, Post Renal Transplantation
Interventions
Cinacalcet, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
15
States / cities
Phoenix, Arizona • Tempe, Arizona • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Oct 29, 2026, 4:53 AM EDT
Recruiting No phase listed Observational

Proteogenomic Monitoring and Assessment of Liver Transplant Recipients

NCT01644903
View directory record Official record
Conditions
Liver Transplant, Hepatitis C, Chronic Kidney Disease, Acute Rejection
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2031
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 29, 2026, 4:53 AM EDT